Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis

Full text
Author(s):
Barreta, Amilcar [1] ; Sarian, Luis Otavio [1] ; Ferracini, Amanda Canato [2] ; Eloy Costa, Larissa Bastos [3] ; Mazzola, Priscila Gava [4] ; Andrade, Liliana de Angelo [3] ; Derchain, Sophie [1]
Total Authors: 7
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, BR-13083970 Campinas, SP - Brazil
[2] Univ Estadual Campinas, Sch Med Sci, Postgrad Program Med Sci, BR-13083970 Campinas, SP - Brazil
[3] Univ Estadual Campinas, Sch Med Sci, Dept Pathol, BR-13083970 Campinas, SP - Brazil
[4] Univ Estadual Campinas, Fac Pharm, BR-13083970 Campinas, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: HUMAN PATHOLOGY; v. 85, p. 72-81, MAR 2019.
Web of Science Citations: 3
Abstract

Ovarian clear cell and endometrioid carcinomas (type I) are thought to develop from endometriosis. AR1D1A loss of expression is known to be related to the promotion of the endometriosis carcinogenesis. Despite the diverse origins and prognosis of type I and type 11 carcinomas, surgery followed by platinum-based chemotherapy is the mainstay of treatment for both. Limited knowledge about the expression of targeted therapies' biomarkers prevents the use of such markers as potential guides for tailored treatment. This study aimed to evaluate the expression of ARID1A gene and target therapies biomarkers (VEGF, PD-L1, and PARP-1) in ovarian clear cell and endometrioid carcinomas and endometriosis, and its relationship with prognosis. Forty-six ovarian clear cell and endometrioid carcinomas, and 24 endometriosis foci samples retrieved from the same surgical specimens were studied. AR1D1A, VEGF, PD-L1, and PARP-1 immunohistochemistry expression was compared in carcinomas and endometriosis with regard to the dinicopathological features and prognosis. We found that endometriosis was associated with increased rates of diagnosis of cancer in the initial stages (P = .008). Different levels of expression of all biomarkers were detected in clear cell and endometrioid carcinomas and endometriosis. However, only the VEGF expression level showed a significant increase in the carcinoma group when compared with endometriosis (P = .0002). PARP-1 overexpression correlated with worse progression-free survival (P = .03) and overall survival (P = .01). In conclusion, endometriosis and ovarian clear cell and endometrioid carcinomas exhibited ARID1A loss of expression, and VEGF, PD-L1, and PARP-1 expression. PARP-1 overexpression in clear cell and endometrioid carcinomas was associated with early recurrence and worse overall survival. (C) 2018 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 12/15059-8 - Evaluation of biomarkers in the detection of malignant neoplasia in women with adnexal mass
Grantee:Sophie Françoise Mauricette Derchain
Support type: Regular Research Grants
FAPESP's process: 16/07822-4 - Analysis Of Molecular Biomarkers Associated To Chemoresistance Derived From Breast Cancer Stem Cells
Grantee:Sophie Françoise Mauricette Derchain
Support type: Regular Research Grants